

**Brighton and Sussex University Hospitals NHS Trust
Study Initiation Q1 2019 - 2020**

| Research Ethics Committee Reference Number | Integrated Research Application System Number | Name of Trial | First Participant Recruited? | Date of First Participant Recruited | Date Site Invited | Date Site Selected | HRA Approval Date | Date Site Confirmed By Sponsor | Date Site Confirmed | Non-Confirmation Status | Date Site Ready To Start | Reasons for Delay | Reasons for delay correspond to: |
|--|---|---|------------------------------|-------------------------------------|-------------------|--------------------|-------------------|--------------------------------|---------------------|-------------------------|--------------------------|--|----------------------------------|
| 18/LO/0727 | 245123 | Post-Market Clinical Follow-Up Study to Monitor Device Performance and Outcomes of the CENTERA Heart Valve System | Yes | 14/02/2019 | 04/07/2018 | 04/07/2018 | 28/02/2018 | 04/07/2018 | 10/09/2018 | Please Select... | 05/10/2018 | D - Sponsor Delays | Sponsor |
| 18/SC/0243 | 240684 | HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease | Yes | 23/03/2019 | 24/07/2018 | 24/07/2018 | 01/10/2018 | 03/10/2018 | 01/10/2018 | Please Select... | 05/12/2018 | D - Sponsor Delays F - No patients seen | Sponsor |
| 17/LO/1711 | 234276 | Synbiotic Extensively Hydrolysed Feed Study | Yes | 08/01/2019 | 04/07/2018 | 25/07/2018 | 14/09/2018 | 25/07/2018 | 31/07/2018 | Please Select... | 14/09/2018 | G - No patients consented | Neither |
| 18/EE/0222 | 233921 | A randomised controlled trial of very early versus delayed angiography +/-intervention on outcomes in patients with non ST-elevation myocardial infarction | Yes | 12/12/2018 | 20/06/2018 | 27/07/2018 | 12/09/2018 | 26/09/2018 | 01/10/2018 | Please Select... | 03/10/2018 | D - Sponsor Delays | Sponsor |
| 18/LO/0997 | 216343 | Brain Imaging to predict Toxicity in Elderly patients after Radiotherapy | Yes | 05/09/2018 | 03/07/2018 | 01/08/2018 | 28/06/2018 | 01/08/2018 | 01/08/2018 | Please Select... | 08/08/2018 | F - No patients seen | Neither |
| 18/NW/0412 | 247770 | To evaluate the acceptability (including gastro intestinal tolerance and compliance) of a low calorie peptide based paediatric tube-feed formula; for children greater than 1 year of age. | No | | 03/08/2018 | 03/08/2018 | 10/07/2018 | 03/08/2018 | 03/08/2018 | Please Select... | 03/08/2018 | F - No patients seen | Neither |

| Research Ethics Committee Reference Number | Integrated Research Application System Number | Name of Trial | First Participant Recruited? | Date of First Participant Recruited | Date Site Invited | Date Site Selected | HRA Approval Date | Date Site Confirmed By Sponsor | Date Site Confirmed | Non-Confirmation Status | Date Site Ready To Start | Reasons for Delay | Reasons for delay correspond to: |
|--|---|---|------------------------------|-------------------------------------|-------------------|--------------------|-------------------|--------------------------------|---------------------|-------------------------|--------------------------|--|----------------------------------|
| 18/LO/0612 | 235872 | CLEAR SYNERGY (OASIS 9): A 2x2 factorial randomized controlled trial of Colchicine and spironolactone in patients with ST elevation myocardial infarction/SYNERGY Stent Registry – Organization to Assess Strategies for Ischemic Syndromes 9 | Yes | 11/02/2019 | 28/05/2018 | 08/08/2018 | 16/07/2018 | 08/08/2018 | 17/09/2018 | Please Select... | 05/12/2018 | D - Sponsor Delays | Sponsor |
| 17/LO/1509 | 232288 | A phase 3 randomised, double blind, clinical trial investigating the effectiveness of repurposed simvastatin compared to placebo, in secondary progressive multiple sclerosis, in slowing the progression of disability | Yes | 23/10/2018 | 13/06/2018 | 18/09/2018 | 19/01/2018 | 12/07/2018 | 24/07/2018 | Please Select... | 18/09/2018 | E - Staff availability issues | NHS Provider |
| 18/LO/0995 | 244737 | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with Advanced | No | | 05/06/2018 | 21/09/2018 | 20/09/2018 | 17/08/2018 | 28/08/2018 | Please Select... | 14/11/2018 | A - Permissions delayed/denied F - No patients seen | NHS Provider |
| 18/LO/0864 | 245423 | Safety & efficacy of Venetoclax + Fulvestrant in ER+ MBC patients | Yes | 31/12/2018 | 03/07/2018 | 03/07/2018 | 19/09/2018 | 30/08/2018 | 04/09/2018 | Please Select... | 07/12/2018 | A - Permissions delayed/denied | Neither |
| 17/LO/2041 | 234256 | Chronic Hypertension in pregnancy implementation study (CHAMPION) | Yes | 01/08/2018 | 05/06/2018 | 09/07/2018 | 11/01/2018 | 09/07/2018 | 09/07/2018 | Please Select... | 09/07/2018 | | Please Select... |

| Research Ethics Committee Reference Number | Integrated Research Application System Number | Name of Trial | First Participant Recruited? | Date of First Participant Recruited | Date Site Invited | Date Site Selected | HRA Approval Date | Date Site Confirmed By Sponsor | Date Site Confirmed | Non-Confirmation Status | Date Site Ready To Start | Reasons for Delay | Reasons for delay correspond to: |
|--|---|--|------------------------------|-------------------------------------|-------------------|--------------------|-------------------|--------------------------------|---------------------|-------------------------|--------------------------|--|----------------------------------|
| 18/WA/0161 | 238902 | An open-label, multi-centre, randomised, switch study to evaluate the virological efficacy over 96 weeks of 2-drug therapy with DTG+RPV FDC in antiretroviral treatment-experienced HIV-1 infected subjects virologically suppressed with NNRTIs resistance mutation | Yes | 18/01/2019 | 08/01/2018 | 06/08/2018 | 04/10/2018 | 13/11/2018 | 13/11/2018 | Please Select... | 13/11/2018 | G - No patients consented | Neither |
| 18/NW/0476 | 246649 | Involve-CAT: A Feasibility Randomised Controlled Trial of a Cataract Decision Aid | Yes | 09/10/2018 | 06/08/2018 | 06/08/2018 | 06/09/2018 | 17/09/2018 | 21/09/2018 | Please Select... | 26/09/2018 | | Please Select... |
| 17/EM/0121 | 221773 | A RANDOMIZED, OPEN, MULTINATIONAL, MULTICENTRE, 2-PART STUDY IN SPONTANEOUSLY BREATHING PRETERM NEONATES WITH MILD TO MODERATE RESPIRATORY DISTRESS SYNDROME TO INVESTIGATE THE SAFETY, TOLERABILITY AND EFFICACY OF INHALED NEBULISED PORACTANT ALFA (PORCINE SURFACTANT, CUROSURF®) IN COMPARISON WITH nCPAP ALONE | No | | 09/07/2018 | 23/08/2018 | 05/03/2019 | 24/09/2018 | 02/10/2018 | Please Select... | 24/04/2019 | D - Sponsor Delays | Sponsor |
| 18/EM/0229 | 250101 | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL-GROUP, ACTIVE-CONTROL STUDY OF THE EFFICACY AND SAFETY OF SPARSENTAN FOR THE | No | | 16/08/2018 | 08/10/2018 | 04/08/2018 | 12/11/2018 | 20/12/2018 | Please Select... | 16/01/2019 | D - Sponsor Delays F - No patients seen | Sponsor |

| Research Ethics Committee Reference Number | Integrated Research Application System Number | Name of Trial | First Participant Recruited? | Date of First Participant Recruited | Date Site Invited | Date Site Selected | HRA Approval Date | Date Site Confirmed By Sponsor | Date Site Confirmed | Non-Confirmation Status | Date Site Ready To Start | Reasons for Delay | Reasons for delay correspond to: |
|--|---|---|------------------------------|-------------------------------------|-------------------|--------------------|-------------------|--------------------------------|---------------------|-------------------------|--------------------------|-----------------------------------|----------------------------------|
| 18/WA/0154 | 233884 | WHITE 8 COPAL: A Randomised Controlled Trial of low dose single antibiotic loaded cement versus high dose dual antibiotic loaded cement in patients receiving a hip hemiarthroplasty after fracture. | Yes | 26/04/2019 | 10/09/2018 | 21/11/2018 | 10/05/2018 | 28/02/2019 | 09/04/2019 | Please Select... | 09/04/2019 | | Please Select... |
| 17/LO/0871 | 215297 | Methylphenidate versus placebo for fatigue in advanced cancer (MePFAC) | Yes | 30/01/2019 | 28/08/2018 | 29/11/2018 | 23/05/2018 | 03/01/2019 | 09/01/2019 | Please Select... | 10/01/2019 | | Please Select... |
| 18/LO/2067 | 253346 | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | Yes | 19/04/2019 | 17/12/2018 | 17/12/2018 | 07/01/2019 | 11/03/2019 | 20/03/2019 | Please Select... | 09/04/2019 | | Please Select... |
| 18/LO/0555 | 237992 | Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal | Yes | 19/06/2019 | 28/01/2019 | 21/03/2019 | 19/04/2018 | 20/03/2019 | 20/05/2019 | Please Select... | 20/05/2019 | | Please Select... |
| 17/YH/0120 | 208838 | A pragmatic multi-centre randomised controlled non-inferiority, cost effectiveness trial comparing injections of collagenase into the cord to surgical correction in the treatment of moderate Dupuytren's Contracture in adult patients. | Yes | 17/05/2019 | 21/12/2018 | 21/12/2018 | 25/05/2017 | 15/04/2019 | 17/04/2019 | Please Select... | 17/04/2019 | | Please Select... |
| 18/WA/0092 | 230113 | USTEKID – Phase II multi-centre, double-blind, randomised trial of Ustekinumab in adolescents with new-onset type 1 diabetes | Yes | 30/05/2019 | 02/01/2019 | 02/01/2019 | 21/09/2018 | 11/02/2019 | 30/04/2019 | Please Select... | 01/05/2019 | | Please Select... |

| Research Ethics Committee Reference Number | Integrated Research Application System Number | Name of Trial | First Participant Recruited? | Date of First Participant Recruited | Date Site Invited | Date Site Selected | HRA Approval Date | Date Site Confirmed By Sponsor | Date Site Confirmed | Non-Confirmation Status | Date Site Ready To Start | Reasons for Delay | Reasons for delay correspond to: |
|--|---|--|------------------------------|-------------------------------------|-------------------|--------------------|-------------------|--------------------------------|---------------------|-------------------------|--------------------------|-----------------------------------|----------------------------------|
| 17/EE/0368 | 213669 | A randomised trial to assess whether the addition of a beta blocker infusion (landiolol) to standard treatment in patients with septic shock, requiring prolonged (>24 hours) support with high-dose vasopressor agents, improves organ failure (the STRESS-L trial) | No | | 10/01/2019 | 03/05/2019 | 10/11/2017 | | | Please Select... | | | Please Select... |
| 19/YH/0151 | 257273 | B7981015 - PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) | No | | 09/11/2018 | 09/05/2019 | | | | Please Select... | | | Please Select... |
| 19/SW/0093 | 260867 | A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 with Background Treatment in Subjects with Lupus Nephritis | No | | 25/04/2019 | 24/05/2019 | 17/06/2019 | 25/04/2019 | | Please Select... | | | Please Select... |
| 19/SC/0021 | 249552 | OPTIMAL TIMING of Anticoagulation after acute ischaemic Stroke: a randomised controlled trial (OPTIMAS Trial) | No | | 13/06/2019 | 13/06/2019 | 04/04/2019 | | | Please Select... | | | Please Select... |
| 19/LO/0905 | 257865 | A Phase IV, Randomised, Open-Label Pilot Study to Evaluate Switching from Protease-Inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in Integrase Inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations. | No | | 17/05/2019 | 28/06/2019 | | | | Please Select... | | | Please Select... |

| Research Ethics Committee Reference Number | Integrated Research Application System Number | Name of Trial | First Participant Recruited? | Date of First Participant Recruited | Date Site Invited | Date Site Selected | HRA Approval Date | Date Site Confirmed By Sponsor | Date Site Confirmed | Non-Confirmation Status | Date Site Ready To Start | Reasons for Delay | Reasons for delay correspond to: |
|--|---|--|------------------------------|-------------------------------------|-------------------|--------------------|-------------------|--------------------------------|---------------------|------------------------------|--------------------------|-----------------------------------|----------------------------------|
| 19/LO/0496 | 259483 | A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis. | No | | 19/12/2018 | 15/01/2019 | | | | Please Select... | | | Please Select... |
| 18/LO/1187 | 240011 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy | Yes | 08/07/2019 | 16/10/2018 | 21/01/2019 | 11/09/2018 | 21/03/2019 | 21/03/2019 | Please Select... | 11/04/2019 | G - No patients consented | Neither |
| 18/NW/0682 | 249138 | Clinical and Cost-effectiveness of Posterior Cervical Foraminotomy versus Anterior Cervical Discectomy in the Treatment of Cervical Brachialgia: A Multicentre, Phase III, Randomised Controlled Trial | No | | 19/02/2019 | 19/02/2019 | 19/11/2018 | | | Site declined to participate | | | Please Select... |
| 19/LO/0040 | 253233 | A PHASE 4, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE IMPACT OF APREMILAST (CC-10004) ON QUALITY OF LIFE, EFFICACY, AND SAFETY IN SUBJECTS WITH MANIFESTATIONS OF PLAQUE PSORIASIS AND IMPAIRED QUALITY OF LIFE | No | | 04/03/2019 | 04/03/2019 | 15/08/2018 | 25/04/2019 | 15/05/2019 | Please Select... | 15/05/2019 | B - Suspended by sponsor | Sponsor |